Biotherapeutic development headwinds require partnership

Partnership

Biotherapeutic development is difficult. Many promising drug candidates discovered early in drug development go through the entire CMC process, only to fail in early clinical trials. Therapeutic modalities, such as genome editing-based medicines, will define the future of medicine. These treatments may be applicable to a broad population or specific to a patient’s unique genotype. These require a holistic approach to minimize time to market. Many genomic medicines are currently undergoing intensive development and will require partnership to surmount future challenges before realizing their potential. In this golden age of biology, stakeholders must unite to improve human health.

Partnership is key to delivering on the promise of the next generation of biotherapeutics. The standardization, scale, and technologies required to quickly bring drugs to market cannot be accomplished alone. We see multiple ways to deliver solutions that can aggregate into critical process improvements:

The Life Sciences companies of Danaher Corporation are applying science and technology to deliver the future of human health. Driven by our culture of continuous improvement and the aim to improve quality of life for billions of people today, we are accelerating innovation and solving our customers’ most complex challenges while setting the foundation for a healthier, more sustainable tomorrow. Talk to an expert at the Life Sciences companies of Danaher Corporation today.